	US 11,951,088 B2
	Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
Stephanie Venn-Watson, San Diego, CA (US); John Reiner, Carlsbad, CA (US); and Richard Lumpkin, San Diego, CA (US)
Assigned to EPITRACKER, INC., San Diego, CA (US)
Filed by Epitracker, Inc., San Diego, CA (US)
Filed on Jul. 17, 2020, as Appl. No. 16/932,508.
Application 16/932,508 is a division of application No. 16/164,573, filed on Oct. 18, 2018, granted, now 10,792,266.
Claims priority of provisional application 62/575,973, filed on Oct. 23, 2017.
Prior Publication US 2020/0345676 A1, Nov. 5, 2020
Int. Cl. A61K 31/20 (2006.01); A61K 31/16 (2006.01); A61K 31/41 (2006.01); A61K 31/421 (2006.01); A61K 31/4245 (2006.01)

CPC A61K 31/20 (2013.01) [A61K 31/16 (2013.01); A61K 31/41 (2013.01); A61K 31/421 (2013.01); A61K 31/4245 (2013.01)]

7 Claims

1. A method of treatment of a condition selected from the group consisting of a pulmonary inflammatory disease and a pulmonary fibrotic disease, the method comprising:

administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of 2-ethylpentadecanoic acid, or a pharmaceutically acceptable salt thereof.